|
|   |
AUTHOR INFORMATION
| Section 1 of 10  |
|
| Author: Klaus-Dieter Lessnau, MD, FCCP, Clinical Assistant Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital Coauthor(s): Farhad Arjomand, MD, Pulmonary Fellow, Department of Internal Medicine, Division of Pulmonary and Critical Care, Brooklyn Hospital Center, Cornell University School of Medicine; Klaus-Dieter Lessnau, MD, FCCP, Clinical Assistant Professor of Medicine, New York University School of Medicine; Medical Director, Pulmonary Physiology Laboratory, Department of Medicine, Section of Pulmonary Medicine, Lenox Hill Hospital |
| Klaus-Dieter Lessnau, MD, FCCP, is a member of the following medical societies:
American College of Chest Physicians,
American College of Physicians,
American Medical Association,
American Society for Artificial Internal Organs,
American Thoracic Society,
Physicians for Social Responsibility, and
Society of Critical Care Medicine |
| Editor(s): Kenneth C Earhart, MD, FACP, Deputy Head, Disease Surveillance Program, United States Naval Medical Research Unit #3; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine;
Richard B Brown, MD, FACP, Chief, Division of Infectious Diseases, Baystate Medical Center; Professor, Department of Internal Medicine, Tufts University School of Medicine;
Eleftherios Mylonakis, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, Assistant in Medicine, Division of Infectious Disease, Massachusetts General Hospital;
and Burke A Cunha, MD, MACP, Professor of Medicine, State University of New York School of Medicine at Stony Brook; Chief, Infectious Disease Division, Winthrop-University Hospital |
Disclosure
|   |
INTRODUCTION
| Section 2 of 10  |
|
Background: Psittacosis is an infection caused by the obligatory intracellular bacterium Chlamydia psittaci. The term psittacosis is derived from the Greek word for parrot, psittakos, and was first used by Morange in 1892.
This bacterium can infect parrots, parakeets, canaries, and other avian species (eg, turkeys, pigeons, ducks). Another term for this infection is ornithosis, which describes the infection caused by nonpsittacine birds.
The largest epidemic occurred in 1930 and affected 750-800 individuals. This epidemic led to the isolation of C psittaci in several laboratories in Europe and the United States.
Psittacosis is an occupational disease of zoo and pet shop employees, poultry farmers, and ranchers. Human-to-human transmission is rare, but possible. These cases may cause more severe disease than avian-acquired psittacosis. Pathophysiology: The primary route for infection is through the respiratory system. Infection develops after inhaling organisms from aerosolized dried avian excreta or respiratory secretions from sick birds. C psittaci attaches to the respiratory epithelial cells. After the initial inoculation, the organism spreads via the blood stream to the reticuloendothelial system. Subsequently, secondary bacteremia causes lung infection.
Humans may acquire disease by handling sick birds. Mouth-to-beak resuscitation also is implicated in transmission. Transient exposure to infected birds may cause symptomatic infection, even in visitors to pet shops. Frequency:
- Internationally: Psittacosis is found worldwide. The incidence seems to be increasing in developed countries, which is correlated to the import of exotic birds.
Mortality/Morbidity: The mortality rate prior to the advent of antimicrobial treatment was approximately 15-20%. The mortality rate is less than 1% with appropriate antibiotic therapy.
Breed: Certain strains of C psittaci infect sheep, goats, and cows and may cause chronic infection and abortion.
- Wild birds such as falcons have caused disease through nasal or fecal secretions.
- Mowing lawns without a grass catcher has been found to be a risk factor.
- Most diseases resulted from exposure to infected pet birds, usually cockatiels, parakeets, parrots, and macaws.
Race: No race predilection is observed.
Sex: No sex predilection is observed.
Age: Psittacosis occurs in all age groups, including children. The infection is more common among individuals in the middle decades of life.
|   |
CLINICAL
| Section 3 of 10  |
|
History: The incubation period generally is 5-14 days. The longest observed incubation time was 54 days. The predominant presentation is respiratory tract infection with constitutional symptoms. Clinical findings are variable. - Cough (50-90%), usually not productive
- Pleuritic chest pain (rare)
- Sore throat and mild pharyngitis (common)
- Nausea and vomiting (uncommon)
- Abdominal pain (uncommon)
- Dermatological - Includes facial rash (Horder spots)
Physical: Disease may range from mild insidious presentations to severe pneumonia that requires mechanical ventilation. - Nonspecific auscultatory findings that often underestimate clinical and radiographic findings may develop.
- Patients may develop fatal pulmonary embolism and pulmonary infarction.
- Pleural effusion is rare.
- Relative bradycardia is common.
- Physicians may observe pericarditis, culture-negative endocarditis, and myocarditis.
- Splenomegaly occurs in 10-70% of patients, depending on the study.
- When present, this sign suggests psittacosis in patients with pneumonia.
- Patients may develop meningitis, encephalitis, seizures, and Guillain-Barré syndrome, but these are rare.
- Cerebrospinal fluid (CSF) findings usually are normal.
- Patients may develop Horder spots, which are macular rashes resembling the rose spots observed in typhoid fever but appearing on the face.
- Patients also may develop erythema multiforme and erythema nodosum.
- Patients may develop anemia secondary to hemolysis.
- Disseminated intravascular coagulation may occur in patients with overwhelming infections.
- Renal symptoms include acute glomerulonephritis and tubulointerstitial nephritis.
- Musculoskeletal symptoms include reactive arthritis that usually is polyarticular. Rarely, rhabdomyolysis has been observed.
- Stages of disease progression
- Flu-like syndromes without radiographic abnormalities
- Mild-to-moderate pneumonia
- Severe pneumonia
- Acute respiratory failure, sepsis, and septic shock
Causes: Psittacosis is an infectious disease caused by the obligatory intracellular bacterium, C psittaci. - C psittaci is associated with psittacine birds and poultry.
- Psittacosis is an occupational disease of poultry farmers, pet shop workers, and veterinarians.
- Since the organism is a bacterium, it is unlikely that major protective immunity will develop after a single episode of disease. The exact risk of recurrence upon reexposure is unknown. It is reasonable to advise advoidance of infected birds.
|   |
DIFFERENTIALS
| Section 4 of 10  |
|
Brucellosis Chlamydial Pneumonias Infective Endocarditis Legionnaires Disease Mycoplasma Infections Pneumonia, Bacterial Pneumonia, Fungal Pneumonia, Viral Q Fever
Tuberculosis Tularemia Typhoid Fever
Other Problems to be Considered:
Coxiella burnetii infection
Francisella tularensis infection
Atypical pneumonia (all causes) |
|
|   |
WORKUP
| Section 5 of 10  |
|
Lab Studies:
- White blood cell counts are normal to mildly decreased.
- Liver function tests are usually mildly increased.
- ESR erythrocyte sedimentation rate (ESR) may be elevated.
- Urinalysis may show mild proteinuria with less than 3500 mg per day.
- Culturing of C psittaci is possible, but this practice is avoided because it can be hazardous to laboratory personnel.
- Test acute-phase serum and convalescent-phase serum 2 weeks after onset to confirm a 4-fold or greater rise in the titer. Complement fixation (CF) is not a specific test and may cross-react with other chlamydial species.
- Physicians use microimmunofluorescence (MIF) and polymerase chain reaction (PCR) studies to detect different chlamydia species. PCR may develop into an early and specific detection test.
- Enzyme-linked immunosorbent assay (ELISA) and direct immunofluorescence (DIF) are experimental in this setting, but physicians have used them to help diagnose C psittaci infection.
- Serologic tests are the mainstays of diagnosis; however, because of the delayed appearance of specific antibodies, these tests are not helpful in emergent clinical management.
Imaging Studies:
- Chest radiographic findings are abnormal in up to 90% of cases.
- The most common finding is unilateral, lower-lobe dense infiltrate/consolidation. Psittacosis may present in a bilateral, nodular, miliary, or interstitial pattern.
- Rarely, patients may develop pleural effusion.
- Chest radiograph abnormalities resolve within an average of 6 weeks (range 3-20 wk).
Other Tests:
- Few patients have CSF abnormalities.
- CDC criteria for C psittaci infection include the following:
- Confirmed cases produce a positive culture result for C psittaci from respiratory secretions, a 4-fold increase in antibody titer in 2 serum samples obtained via CF or MIF 2 weeks apart, or immunoglobulin M (IgM) antibodies against C psittaci, as detected by MIF to a reciprocal titer of 16.
- Possible cases show the presence of antibodies against C psittaci with titers of 1:32 by CF or MIF.
Histologic Findings: Findings may include tracheobronchitis and interstitial pneumonitis with air space involvement and predominant mononuclear cell infiltration. Findings also may include macrophages containing cytoplasmic inclusion bodies (ie, Levinthal-Coles-Lillie [LCL] bodies), focal necrosis of hepatocytes along with Kupffer cell hyperplasia in the liver, and hepatic noncaseating granulomata.
|   |
TREATMENT
| Section 6 of 10  |
|
Medical Care: Consider the diagnosis of psittacosis in patients with community-acquired pneumonia who have had exposure to birds. The mainstay of medical care is antibiotic therapy. Consultations: - Notify public health authorities about cases of psittacosis.
- Obtain infectious disease consultation.
Diet: Patients require no specific diet. Activity: Patients do not require activity restrictions.
|   |
MEDICATION
| Section 7 of 10  |
|
The goals of pharmacotherapy are to reduce morbidity and to prevent complications.
Drug Category: Antibiotics -- Empiric antimicrobial therapy must be comprehensive and should cover all likely pathogens in the clinical setting. Tetracycline and doxycycline are the antibiotics of choice. Treating patients for 2-3 weeks usually prevents relapse. Clinical response occurs within 24-72 hours. Use erythromycin in children younger than 9 years and in pregnant women. Chloramphenicol is a third alternative antibiotic.
Doxycycline remains the drug of choice. Macrolide and quinolone failures have been observed. Drug Name
| Doxycycline (Vibramycin) -- DOC; inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. Continue treatment for at least 2 wk to prevent relapse. |
|---|
| Adult Dose | 100 mg PO bid Severe cases: 4.4 mg/kg IV q12h |
|---|
| Pediatric Dose | <8 years: not recommended
>8 years and <100 lb: 2 mg/kg/d in PO/IV in 1-2 divided doses on day 1; then 1-2 mg/kg/d in 1-2 divided doses; not to exceed 200 mg/d
>8 years and >100 lb: Administer as in adults| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Bioavailability decreases slightly with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Photosensitivity is very rare with prolonged exposure to sunlight; avoid during last half of pregnancy through 8 y |
|---|
|
|---|
Drug Name
| Erythromycin (E-Mycin, Ery-Tab, E.E.S.) -- Macrolide antibiotic; second DOC. Inhibits bacterial growth, possibly by blocking dissociation of peptidyl t-RNA from ribosomes, causing RNA-dependent protein synthesis to arrest. For treatment of staphylococcal and streptococcal infections. In children, age, weight, and severity of infection determine proper dosage. When bid dosing is desired, administer half total daily dose q12h. For more severe infections, double the dose. |
|---|
| Adult Dose | 500 mg erythromycin stearate/base (or 800 mg ethylsuccinate) PO qid 1 h ac for 2-3 wk Alternatively, use 333 mg q8h; increase up to 4 g/d, depending on severity of infection |
|---|
| Pediatric Dose | 30-50 mg/kg/d (15-25 mg/lb/d) PO divided q6-8h; double dose for severe infection |
|---|
| Contraindications | Documented hypersensitivity; hepatic impairment |
|---|
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
|---|
| Pregnancy |
B - Usually safe but benefits must outweigh the risks.
|
|---|
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; GI adverse effects are common (administer doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
|---|
Drug Name
| Chloramphenicol (Chloromycetin) -- Third DOC but rarely used in the US. Binds to 50S bacterial-ribosomal subunits and inhibits bacterial growth by inhibiting protein synthesis. Effective against gram-negative and gram-positive bacteria. |
|---|
| Adult Dose | 500 mg IV qid for 2-3 wk |
|---|
| Pediatric Dose | 50-100 mg/kg/d IV divided q6h for 2-3 wk |
|---|
| Contraindications | Documented hypersensitivity |
|---|
| Interactions | Concurrently with barbiturates, chloramphenicol serum levels may decrease while barbiturate levels may increase and cause toxicity; manifestations of hypoglycemia may occur with sulfonylureas; rifampin may reduce serum chloramphenicol levels, presumably through hepatic enzyme induction; may increase effects of anticoagulants; may increase serum hydantoin levels, possibly resulting in toxicity; chloramphenicol levels may be increased or decreased |
|---|
| Pregnancy |
D - Unsafe in pregnancy
|
|---|
| Precautions | Use only for indicated infections, or as prophylaxis for bacterial infections; serious and fatal blood dyscrasias (ie, aplastic anemia, hypoplastic anemia, thrombocytopenia, granulocytopenia) can occur; evaluate baseline and perform periodic blood studies approximately every 2 d while in therapy; discontinue upon appearance of reticulocytopenia, leukopenia, thrombocytopenia, anemia, or findings attributable to chloramphenicol; adjust dose in liver or kidney dysfunction; caution in pregnancy at term or during labor because of potential toxic effects on fetus (ie, gray syndrome) |
|---|
|   |
FOLLOW-UP
| Section 8 of 10  |
|
Further Inpatient Care:
- Severe infection requires IV antibiotics and hospital admission.
- Isolation is not indicated during hospital stay.
Further Outpatient Care:
- Instruct patients to see a physician if symptoms recur (ie, relapse).
- Patients with relapses may need prolonged retreatment (eg, 3-4 wk).
In/Out Patient Meds:
- Patients may require doxycycline, usually 100 mg IV; alternatively, consider PO administration with the same dose twice a day.
- Chloramphenicol is the third drug of choice, but it rarely is used in the United States.
- Consider changing erythromycin from IV to PO administration (eg, 500 mg qid).
- Chloramphenicol rarely is used in the United States because it may cause agranulocytosis.
- Consider changing quinolones from IV to PO administration.
Transfer:
- Transfer patients with acute respiratory failure to an intensive care unit.
Deterrence/Prevention:
- Instruct high-risk individuals to avoid handling newly imported or sick birds.
Complications:
- Acute respiratory failure
- Culture-negative endocarditis
- Renal failure (rare, only a few case reports)
- Disseminated intravascular coagulation (rare)
- Arterial embolism (rare, 2 case reports)
- Transverse myelitis
- Meningitis or encephalitis
Prognosis:
- With appropriate antibiotic therapy, the mortality rate is less than 1%.
- A poor prognosis is associated with hypoxemia and renal failure.
Patient Education:
- Warn pet owners and pet shop and poultry workers to be aware of possible respiratory symptoms and fever.
|   |
MISCELLANEOUS
| Section 9 of 10  |
|
Medical/Legal Pitfalls:
- Failure to make the proper diagnosis is a medicolegal pitfall. (Psittacosis may be easily overlooked, but adherence to published guidelines for the management of community-acquired pneumonia covers this pathogen.)
- Failure to realize that the natural history of the disease carries approximately 15% mortality and the concomitant need for appropriate empiric therapy.
- Failure to maintain a high index of suspicion
- Failure to inquire about bird exposure and occupational considerations
- Failure to realize that doxycycline is not recommended for children because it may cause tooth discoloration
Special Concerns:
- Educate high-risk individuals about the symptoms of psittacosis. These individuals include zoo workers and pet shop owners, among others. Individuals must keep accurate records of all bird transactions.
- Avoid purchasing or selling birds that have ocular or nasal discharge, diarrhea, or low body weight.
- Isolate imported and exotic birds for 30-45 days. Test these birds, or treat them with prophylaxis.
|   |
BIBLIOGRAPHY
| Section 10 of 10 |
|
-
Committee of the National Association of State Public Health Veterinarians: Compendium of measures to control Chlamydia psittaci infection among humans (psittacosis) and pet birds (avian chlamydiosis), 2000. Centers for Disease Control and Prevention. Morbidity Mortality Weekly Reports 2000; 49: 3-17[Medline].
-
Coutts II, Mackenzie S, White RJ: Clinical and radiographic features of psittacosis infection. Thorax 1985 Jul; 40(7): 530-2[Medline].
-
Crosse BA: Psittacosis: a clinical review. J Infect 1990 Nov; 21(3): 251-9[Medline].
-
Cunha BA, Quintiliani R: The atypical pneumonias: a diagnostic and therapeutic approach. Postgrad Med 1979 Sep; 66(3): 95-102[Medline].
-
Cunha BA: Atypical pneumonias. Clinical diagnosis and empirical treatment. Postgrad Med 1991 Oct; 90(5): 89-90, 95-8, 101[Medline].
-
Cunha BA, Ortega AM: Atypical pneumonia. Extrapulmonary clues guide the way to diagnosis. Postgrad Med 1996 Jan; 99(1): 123-8, 131-2[Medline].
-
Cunha BA: Atypical pneumonias. In: Conn RB, Borer WZ, Snyder JW, eds. Current Diagnosis. WB Saunders Co; 1996.
-
Cunha BA: The chlamydial pneumonias. Drugs Today (Barc) 1998 Dec; 34(12): 1005-12[Medline].
-
De Schrijver K: A psittacosis outbreak in Belgian customs officers. Euro Surveillance 1995; Sep: 3[Medline].
-
Elliott JH: Psittacosis. A flu like syndrome. Aust Fam Physician 2001 Aug; 30(8): 739-41[Medline].
-
Entrican G, Brown J, Graham S: Cytokines and the protective host immune response to Chlamydia psittaci. Comp Immunol Microbiol Infect Dis 1998 Jan; 21(1): 15-26[Medline].
-
Gherman RB, Leventis LL, Miller RC: Chlamydial psittacosis during pregnancy: a case report. Obstet Gynecol 1995 Oct; 86(4 Pt 2): 648-50[Medline].
-
Gregory DW, Schaffner W: Psittacosis. Semin Respir Infect 1997 Mar; 12(1): 7-11[Medline].
-
Heddema ER, Kraan MC, Buys-Bergen HE: A woman with a lobar infiltrate due to psittacosis detected by polymerase chain reaction. Scand J Infect Dis 2003; 35(6-7): 422-4[Medline].
-
Hughes P, Chidley K, Cowie J: Neurological complications in psittacosis: a case report and literature review. Respir Med 1995 Oct; 89(9): 637-8[Medline].
-
IVD industry: The latest from the IVD industry December 2004. Chlamydia--pathogens that are still often underestimated. Clin Lab 2005; 51(3-4): 225-9[Medline].
-
Jaton K, Greub G: [Chlamydia: diagnostic and treatment]. Rev Med Suisse 2005 Mar 30; 1(13): 895-8, 901-3[Medline].
-
Johnson DH, Cunha BA: Atypical pneumonias. Clinical and extrapulmonary features of Chlamydia, Mycoplasma, and Legionella infections. Postgrad Med 1993 May 15; 93(7): 69-72, 75-6, 79-82[Medline].
-
Kirchner JT: Psittacosis. Is contact with birds causing your patient's pneumonia? Postgrad Med 1997 Aug; 102(2): 181-2, 187-8, 193-4[Medline].
-
MacLaren G, Pellegrino V, Butt W: Successful use of ECMO in adults with life-threatening infections. Anaesth Intensive Care 2004 Oct; 32(5): 707-10[Medline].
-
Matsushima H, ,, Takayanagi N, Ubukata M: [A case of fulminant psittacosis with rhabdomyolysis]. Nihon Kokyuki Gakkai Zasshi. Jul;(7): 2002; 40: 612-6[Medline].
-
Nash TW, Murray HW: The atypical pneumonias. In: Fishman AP, ed. Pulmonary diseases and disorders. Vol 2. 2nd ed. New York, NY: McGraw-Hill; 1998: 1619-24.
-
Oldach DW, Gaydos CA, Mundy LM, et al: Rapid diagnosis of Chlamydia psittaci pneumonia. Clin Infect Dis 1993 Sep; 17(3): 338-43[Medline].
-
Raso Tde F, Godoy SN, Milanelo L: An outbreak of chlamydiosis in captive blue-fronted Amazon parrots (Amazona aestiva) in Brazil. J Zoo Wildl Med 2004 Mar; 35(1): 94-6[Medline].
-
Schlossberg D: Chlamydia psittaci (psittacosis). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases
. 5th ed. Philadelphia, Pa: Churchill Livingstone; 2000: 2004-6.
-
Schlossberg D, Delgado J, Moore MM, et al: An epidemic of avian and human psittacosis. Arch Intern Med 1993 Nov 22; 153(22): 2594-6[Medline].
-
Smith KA, Bradley KK, Stobierski MG: Compendium of measures to control Chlamydophila psittaci (formerly Chlamydia psittaci) infection among humans (psittacosis) and pet birds, 2005. J Am Vet Med Assoc 2005 Feb 15; 226(4): 532-9[Medline].
-
Stamm WE: Chlamydial infection: psittacosis. In: Braunwald E, et al, eds. Harrison's Principles of Internal Medicine. 14th ed. New York, NY: McGraw Hill; 1998:1055-64.
-
Telfer BL, Moberley SA, Hort KP: Probable psittacosis outbreak linked to wild birds. Emerg Infect Dis 2005 Mar; 11(3): 391-7[Medline].
-
Tong CY, Sillis M: Detection of Chlamydia pneumoniae and Chlamydia psittaci in sputum samples by PCR. J Clin Pathol 1993 Apr; 46(4): 313-7[Medline].
-
Verweij PE, Meis JF, Eijk R, et al: Severe human psittacosis requiring artificial ventilation: case report and review. Clin Infect Dis 1995 Feb; 20(2): 440-2[Medline].
-
Wong KH, Skelton SK, Daugharty H: Utility of complement fixation and microimmunofluorescence assays for detecting serologic responses in patients with clinically diagnosed psittacosis. J Clin Microbiol 1994 Oct; 32(10): 2417-21[Medline].
Psittacosis excerpt |